View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Statement of total voting rights and shares forming the company’s shar...

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025 Article R. 22-10-23 of the French Commercial Code Market: Euronext ParisISIN code / Mnemo: FR0013233012 / IVAWeb site: DateNumber of shares outstandingTotal voting rights,gross (1)Total voting rights,net (2)April 11, 202595,662,391108,635,435108,574,827 The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to w...

 PRESS RELEASE

Information relative au nombre total de droits de vote et d’actions co...

Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2025 Article R. 22-10-23 du Code de commerce Place de cotation : Euronext ParisCode ISIN / Mnémo : FR0013233012 / IVASite web :   Date Nombre de titres composant le capital en circulation   Nombre total de droits de vote bruts(1)   Nombre total de droits de vote nets(2) 11 avril 2025 95 662 391 108 635 435 108 574 827 Le nombre de droits de vote bruts (ou droits de vote « théoriques ») sert de base de calcul pour les franchissements de seuil. Conformément à l’articl...

 PRESS RELEASE

Combined General Meeting of May 22, 2025 - Availability of the prepara...

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of Ma...

 PRESS RELEASE

Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposit...

Assemblée Générale Mixte du 22 mai 2025 - Modalités de mise à disposition des documents préparatoires Daix (France), New York City (New York, Etats-Unis), le 30 avril 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d’autres maladies avec un besoin médical non satisfait, annonce aujourd’hui les modalités de mise à disposition des documents pré...

Guy Sips ... (+10)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : COFB BB, CRBN NA, OPTI BB, GLPG NA, IVA FP, MTLS US, Q...

: COFB BB, CRBN NA, OPTI BB, GLPG NA, IVA FP, MTLS US, QFG BB, SOF BB, UMI BB, WDP BB, XIOR BB, IMCD NA

Jacob Mekhael
  • Jacob Mekhael

Inventiva Publishes results on predictive biomarker in MASH in journal

Inventiva announced publication in the peer-reviewed medical journal Clinical Gastroenterology and Hepatology, of its analysis on new non-invasive biomarker signatures predictive of histology response following treatment with lanifibranor (pan-PPAR agonist) in patients with MASH and fibrosis. While there are multiple diagnostic scores currently available, we are encouraged to learn that Inventiva's test suggested better predictive accuracy than existing options including FIB4. With recruitment i...

 PRESS RELEASE

Bekaert - Update on the Share Buyback Program and Liquidity Agreement

Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 17 April 2025 to 23 April 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 17 April 2025 to 23 April 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 40 953 shares. The table belo...

 PRESS RELEASE

Bekaert - Mise à jour relative au Programme de Rachat d’Actions et au ...

Bekaert - Mise à jour relative au Programme de Rachat d’Actions et au contrat de liquidité Veuillez trouver en annexe le communiqué de presse disponible en anglais et en néerlandais.  Pièces jointes

 PRESS RELEASE

Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...

Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 17 april 2025 tot 23 april 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 17 april 2025 tot 23 april 2025, Kepler Cheuvreux i...

 PRESS RELEASE

Inventiva announces the publication in Clinical Gastroenterology and H...

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► ...

 PRESS RELEASE

Inventiva annonce la publication dans Clinical Gastroenterology and He...

Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor ► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la résolution de la MASH et les critères histologiques composites, ont suggéré une meilleure prédictivité que les ...

 PRESS RELEASE

Bekaert - Update on the Share Buyback Program and Liquidity Agreement

Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 10 April 2025 to 16 April 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 10 April 2025 to 16 April 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 69 183 shares. The table belo...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch